Technology company Clario has published a roadmap for the use of artificial intelligence (AI) to enhance the experience of patients in decentralised clinical trials (DCTs).

Published in Nature Medicine, the manuscript explores the way AI practices can be beneficial for participants and improve the collected data’s quality and accuracy in trials.

The latest move comes as remote trials continue to increase in popularity and place increased responsibility on subjects.

The study also explores how AI automation can support digital health user interface improvements.

Clario Artificial Intelligence director Kevin Thomas said: “AI is being used to enhance user experience in customer-facing applications across many industries.

“Adopting this approach in clinical trials means we can help more patients to enrol, empower them to complete trials without undue burden, and ensure they are able to submit high-quality health assessments throughout their participation.”

Thomas and coauthor Łukasz Kidziński, who is also the Clario Artificial Intelligence director, suggested various AI domains that can be used for customer experience improvement in clinical trials.

The domains include reinforcement learning, computer vision, and temporal data AI models.

Used for optimising notifications on social media platforms, reinforcement learning can customise notifications for participants and help them fit eCOA tasks into their schedule.

Computer vision can empower users to quickly submit their medical photos if deployed in trials.

Mobility trials that rely on wearable sensors can use temporal data AI models which could be trained to infer how a body part moves based on obtained data at a different part.

In May this year, Clario and Cogstate expanded their collaboration to jointly offer data collection and quality solutions for neuroscience clinical trials.